Last Update: 03-Jan-13 10:29 ET
The Healthcare sector (-0.29%) is trading lower today, slightly underperforming the S&P 500
General Commentary: BG Medicine (BGMD) shares are up nearly 20% today. Yesterday after the close the company announced that the first automated version of the BGM Galectin-3 blood test has obtained a CE Mark. BG said that this is, "an important step in the company's commercial strategy." The test will be be distributed through bioMerieux's VIDAS immunoassay platform which includes about 27,000 installed instruments worldwide. Analysts at Mizuho said that while expected, the approval adds to their confidence in management's ability to execute on its commercial development strategy, and follows up the European approval of BG's CardioSCORE test in December 2012. They continue to await FDA approval for Abbott's (ABT) automated Galectin-3 test, which was submitted to the FDA in July 2012; they expect approval in early 2013.
General Commentary: BG Medicine (BGMD) shares are up nearly 20% today. Yesterday after the close the company announced that the first automated